Katja Schindler - Concepedia

Author

Katja Schindler

Medical University of Vienna

Also Known As

K Schindler, K. Schindler, Katja Schindler, Schindler, Katja

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Medical University of Vienna Memorial Sloan Kettering Cancer Center Vienna General Hospital University Hospital of Zurich Cornell University

About

Katja Schindler is an author at Medical University of Vienna specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	447
2	Immunology	4	4	400
3	Pathology	3	3	324
4	Health Sciences	2	2	51
5	Surgical Oncology	1	1	14

Katja Schindler

Publications

493

Citations

H-Index

Page 1

	Year	Citations
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1 Jarushka Naidoo, Katja Schindler, Christiane Querfeld, Cancer Immunology Research ImmunodeficienciesImmunologyPathologyDermatologyImmunotherapy	2016	277
Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. Katja Schindler, Kaan Harmankaya, Deborah Kuk, Journal of Clinical Oncology ImmunologyImmunoeditingEosinophilic DisorderDermatologyImmune System	2014	72
Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series V. Sibaud, Rachel Niec, Katja Schindler, Breast Cancer Research and Treatment Metastatic Breast CancerBreast OncologyMedicinePathologyBreast Cancer	2014	33
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival? Joanna Mangana, Phil F. Cheng, Katja Schindler, PLoS ONE	2015	31
Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody. Katja Schindler, Kaan Harmankaya, Michael A. Postow, Journal of Clinical Oncology ImmunodeficienciesImmunologyImmunoeditingImmunotherapeuticsEosinophilic Disorder	2013	29
What does the future hold for immunotherapy in cancer? Jarushka Naidoo, Bob T. Li, Katja Schindler, Annals of Translational Medicine Future HoldImmunologyImmunoeditingImmune Checkpoint AntibodiesImmunotherapeutics	2016	22
Beyond the dose‐limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program Alexander Drilon, Anne Eaton, Katja Schindler, Cancer	2016	15
A rare case of primary rhabdoid melanoma of the urinary bladder treated with ipilimumab, an anti-CTLA 4 monoclonal antibody Katja Schindler, Nikolaus Schicher, Rainer Kunstfeld, Melanoma Research Rhabdoid MelanomaUrologySurgical OncologyTumoral PathologyGenitourinary Cancer	2012	14

Page 1